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IMPORTANCE Very preterm infants are at risk of developing encephalopathy of prematurity
and long-term neurodevelopmental delay. Erythropoietin treatment is neuroprotective in
animal experimental and human clinical studies.
OBJECTIVE To determine whether prophylactic early high-dose recombinant human
erythropoietin (rhEPO) in preterm infants improves neurodevelopmental outcome at 2 years’
corrected age.
DESIGN, SETTING, AND PARTICIPANTS Preterm infants born between 26weeks 0 days’ and 31
weeks 6 days’ gestation were enrolled in a randomized, double-blind, placebo-controlled,
multicenter trial in Switzerland between 2005 and 2012. Neurodevelopmental assessments
at age 2 years were completed in 2014.
INTERVENTIONS Participants were randomly assigned to receive either rhEPO (3000 IU/kg)
or placebo (isotonic saline, 0.9%) intravenously within 3 hours, at 12 to 18 hours, and at 36 to
42 hours after birth.
MAIN OUTCOMES ANDMEASURES Primary outcomewas cognitive development assessed
with theMental Development Index (MDI; norm, 100 [SD, 15]; higher values indicate better
function) of the Bayley Scales of Infant Development, second edition (BSID-II) at 2 years
corrected age. Theminimal clinically important difference between groups was 5 points
(0.3 SD). Secondary outcomes weremotor development (assessed with the Psychomotor
Development Index), cerebral palsy, hearing or visual impairment, and anthropometric
growth parameters.
RESULTS Among 448 preterm infants randomized (mean gestational age, 29.0 [range,
26.0-30.9] weeks; 264 [59%] female; mean birth weight, 1210 [range, 490-2290] g), 228
were randomized to rhEPO and 220 to placebo. Neurodevelopmental outcome data were
available for 365 (81%) at a mean age of 23.6months. In an intention-to-treat analysis, mean
MDI was not statistically significantly different between the rhEPO group (93.5 [SD, 16.0]
[95% CI, 91.2 to 95.8]) and the placebo group (94.5 [SD, 17.8] [95% CI, 90.8 to 98.5])
(difference, −1.0 [95% CI, −4.5 to 2.5]; P = .56). No differences were found between groups in
the secondary outcomes.
CONCLUSIONS AND RELEVANCE Among very preterm infants who received prophylactic early
high-dose rhEPO for neuroprotection, compared with infants who received placebo, there
were no statistically significant differences in neurodevelopmental outcomes at 2 years.
Follow-up for cognitive and physical problems that may not become evident until later in life
is required.
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A lthoughoutcome in very preterm infants has improvedin recentdecades, theystill experiencesignificant long-termneurodevelopmentaldelay.Theunderlyingpathol-
ogy is termed encephalopathy of prematurity, as visualized by
magnetic resonance imaging (MRI).1Amongseveralpharmaco-
logical candidates to prevent brain injury or improve develop-
ment,erythropoietin(EPO)hasbeenshowntobeamongthemost
promising.2EPOstimulateserythroidcellproliferation,survival,
and differentiation.3 More recent evidence suggests a role of
EPOintissuedevelopmentandprotection,4andEPOreceptorex-
pressionhasbeenobserved inother cell types suchasendothe-
lial, glial, andneuronal cells.5Animalexperiments firstdemon-
stratedneuroprotectiveactivityofEPO.6Potentialmechanisms
explaining this action include inhibition of glutamate release,
modulation of intracellular calciummetabolism, generation of
antiapoptotic factors, and anti-inflammatory and antioxidant
effects.7Thesepreclinicaldatafoundsupportintheresultsofclini-
cal trials assessing theneuroprotective role of recombinanthu-
man EPO (rhEPO) in term-born infants with hypoxic ischemic
encephalopathy8andstroke.9RetrospectivestudiesusingrhEPO
foranemiaandarecenttrialshowedthatEPOalsoimprovesneu-
rodevelopmentaloutcomeinpreterminfants.10,11Thesestudies,
however,were relativelysmall.Tocross theblood-brainbarrier,
EPOhas tobeadministered inhighdosesof2000to5000IU/kg
of bodyweight. These high doses arewell tolerated in preterm
infants.Ashort treatmentperiodsufficient toblockbrain recep-
torsdidnot increase the risk for retinopathyofprematurity,12 in
contrast towhathasbeen reportedafter treatmentover several
weeks.13 An association has been reported between early high-
doserhEPOandareducedincidenceofwhiteandgraymatter in-
juriesassessedbycerebralMRI inasubgroupofverypretermin-
fantsattermequivalentfromthistrial.14,15Thisarticlereportsthe
prespecifiedprimaryoutcome,theeffectofearlyhigh-doserhEPO
onneurodevelopmental outcome at 2 years.
Methods
Study Design
This phase 3 study was designed as a randomized, double-
blind, placebo-controlled, multicenter trial with 1:1 allocation
ofpatients tohigh-dose rhEPOorplacebo. Five Swissperinatal
centers, 3 university hospitals (Basel, Geneva, and Zurich) and
2districthospitals (AarauandChur),were includedinthestudy.
Enrollment occurred between 2005 and 2012,with the date of
last neurodevelopmental evaluation in 2014. Vials containing
the study drug were prepared in the pharmacy of Zurich Uni-
versityHospital according to a randomization list stratifiedper
center and labeled, shipped, and stored according to the Swiss
TherapeuticProductsAct.16The randomization listwasknown
only to thepharmacist. Parents, physicians, nurses, and exter-
nal statisticianswereunawareof treatmentallocation.All neu-
rodevelopmentalassessmentswereconductedinablindedman-
ner. Approval to conduct this studywas granted by the ethical
committeeof theZurichUniversityChildren’sHospital, theethi-
calcommitteeofCantonZurich,andtheSwissAgencyforThera-
peutic Products (Swissmedic). Written informed consent was
obtained from the parents of eligible infants.
Study Population
The study protocol (Supplement 1) has been described
previously.17 Briefly, very preterm infants born between 26
weeks 0 days’ and 31weeks 6 days’ gestationwere eligible for
enrollment within the first 3 hours after birth. Exclusion cri-
teria were a genetically defined syndrome, a severe congeni-
tal malformation adversely affecting life expectancy or neu-
rodevelopment, severe intraventricular hemorrhage before
randomization, and a priori palliative care.
Intervention
rhEPOor anequivalent volumeof isotonic saline (NaCl, 0.9%)
placebowas administered intravenously before 3 hours, at 12
to 18hours, andat 36 to42hours after birth.A singledose con-
sisted of 25μg (3000 IU) rhEPO per kg of body weight dis-
solved in 1mLdistilledwater. OnemLper kg birthweightwas
administered intravenously during aperiodof 3minutes. The
maximal dose was 1.5 mL (37.5μg [4500 IU]) rhEPO for in-
fantsweighing 1.5 kgormore. Similarly, theplacebodose con-
sisted of 1 mL of NaCl (0.9%) per kilogram birth weight.
Monitoring
Serial cerebral ultrasound assessment was carried out on day
1, days 7 to 10, and then every 14 days until 36 weeks 0 days’
postmenstrual age or at discharge if discharged before. Study
drug and all other medications were documented, as well as
any complications.
TheSwissmedic temporarily suspended the studyafter an
infant in the studydiedof severe intracranial hemorrhage and
theparents lodgeda claim for compensation.Theparents con-
sidered this critical event to be attributable to the experimen-
tal drug; disclosure of group allocation revealed that the in-
fant was in the rhEPO group. The ethics committees and
Swissmedic asked for a review by independent experts, who
concluded that therewasno evidence for a causal relationbe-
tween rhEPOand intracranial hemorrhage.Neither the inves-
tigatorsnor the statisticianswere involved in the reviewby the
independent experts and remained blinded to the outcomes.
After an 11-month hold, enrollment continued with the fol-
lowing constraint: Infants with hemorrhage grade 2 or more
detected before dose 3 of rhEPO had to be excluded.
Definition of Neonatal and Demographic Variables
Gestational agewasdefinedas thebest estimateavailable from
obstetricmeasurements basedon the lastmenstrual periodor
prenatalultrasoundfindings, as recorded in thematernal chart.
Z scores foranthropometricmeasureswerecalculatedbasedon
thegrowthcurvesbyVoigtetal.18Majorbrain injurywasdefined
by cerebral ultrasoundexamination as severe intraventricular
hemorrhage, ie,grade2ormoreaccordingtoVolpe,19cysticperi-
ventricular leukomalacia,20 or both. Bronchopulmonary dys-
plasia was defined as requirement for additional oxygen at 36
weeks0days’postmenstrual age.21Retinopathyofprematurity
wasdefinedusing the InternationalCommittee criteria.22Nec-
rotizing enterocolitis was defined as pneumatosis intestinalis
orportalvenousgas (Bell stage≥2).23 Infectionwasclassifiedas
uninfectedorprovensepsis (positivebloodorcerebrospinal fluid
culture).24 Socioeconomic statuswasestimatedbyavalidated
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12-point socioeconomicscorebasedonmaternaleducationand
paternal occupation andwas classified intohigher class (score
2-5), middle class (6-8), and lower class (9-12).25
Outcome Assessment
Neurodevelopmentalexaminationwasperformedat2years’cor-
rectedagebyexperienceddevelopmentalpediatriciansorneu-
ropediatriciansat5 follow-upsitesattachedtotheperinatalcen-
ters participating in the study. Examinations were videotaped
and regularmeetings of the investigatorswere scheduled. The
assessmentconsistedofaclinicalexaminationincludinganthro-
pometricmeasurement,astructuredneurologicassessment,and
adevelopmentalassessmentusingtheBayleyScalesofInfantDe-
velopment, secondedition (BSID-II).26 Infantswhowere so se-
verelyimpairedthatstructuredtestingwiththeBSID-IIcouldnot
beperformedwereassignedamentaldevelopment index (MDI)
andpsychomotordevelopment index (PDI)of49 (≤3SD).Norm
valueofbothMDIandPDI is 100 (SD, 15),withhighvalues indi-
cating better function. Cerebral palsywas graded according to
theGrossMotorFunctionClassificationSystemofPalisanoetal27
forchildren2yearsoryounger.Visionandhearingwereassessed
either bydirect examinationor parents’ report. Severehearing
impairmentwasdefinedas theabsenceofusefulhearing, even
withaids(ie,>90dBhearinglevel);severevisual impairmentwas
definedasblindnessoronlyperceptionof lightor light-reflecting
objects. Thecompositeoutcomecategory“severeneurodevel-
opmental impairment”was defined as 1 ormore of the follow-
ing: a BSID-II index less than 2 SDs below themean (ie,MDI or
PDI <70); cerebral palsywith GrossMotor Function Classifica-
tion System level 3 to 5; severe hearing or visual impairment.
Outcomes
The primary outcome was the MDI at 2 years’ corrected age,
while secondary outcomes were motor development as as-
sessed by the PDI; cerebral palsy, severe hearing impairment,
and severe visual impairment; and weight, length, and head
circumference. Post hoc exploratory outcomes were defined
as the binary outcomes of MDI or PDI less than 70, which are
indicative for neurodevelopmental impairment, and the com-
posite outcome survival without severe neurodevelopmen-
tal impairment.Reports of other secondaryoutcomes, ie, neo-
natal outcomes12 and cerebralMRI14,15 at term equivalent in a
subgroupofstudy infants,havealreadybeenassessedandpub-
lished. No excess in mortality or major adverse events were
found in the rhEPO group vs placebo at hospital discharge.12
An association between early high-dose rhEPOand a reduced
incidence of white and gray matter injuries was found.14,15
Statistical Analysis
The study hypothesis was that the mean MDI at 2 years’ cor-
rectedage in the rhEPOgroupwas5points (0.3SD)higher than
in the placebo group, based on the experience of the investi-
gators and other study groups. A minimal sample size of 176
infants per group was calculated, assuming a 2-sided α error
of .05 and a power (1 − β) of 0.8. To compensate for dropouts,
we added 20%, targeting at least 211 infants per group. χ2 test
and independent t test were used to compare baseline char-
acteristics between groups.
Theprimary investigationwas an intention-to-treat (ITT)
analysis, the infants being compared according to the treat-
ment theywere assignedat studyentry. Theunadjusted treat-
ment effect was determined using a linear regression model,
which is equivalent to an unpaired t test. Themodel assump-
tionwas that theobservations inbothgroupscome fromanor-
mal distribution. This assumption was not violated.
Anunadjusted per-protocol analysiswas also performed,
restricted to patients whowere actually treated as in the pro-
tocol.Thesametypeof ITTandper-protocolanalyseswereper-
formed for all secondary and exploratory outcomes.
Twopost hoc exploratory investigations of the ITT analy-
sis of the primary outcome were performed. First, a sensitiv-
ity analysis including the25 infantswhodiedbefore follow-up
and sowere excluded fromtheprimary investigationwasper-
formed by imputing the worst MDI, ie, 49. Second, analyses
of subgroups of study infantswith especially high risk for de-
velopmental delay were performed; ie, infants with gesta-
tional age less than 28 weeks and infants with intraventricu-
lar hemorrhage grade 2 or higher. In addition, the MDI in the
subset of infants included in the previous examination of the
associationofearlyhigh-doserhEPOandthe incidenceofwhite
andgraymatter injuriesat termequivalentwasdetermined.14,15
Results concerning the primary and secondary outcomes
were reportedwith95%CIsand99%CIs, respectively.Weused
multiple imputation formissingvalues. Statistical analysiswas
performed using R version 3.1.028; the significance threshold
was defined as P < .05 (2-sided).
Results
Study Population
Of1359 live-born infantswithin the targetgestationalage range,
450wereenrolledandrandomized(Figure)(meangestationalage,
29.0 [range, 26.0-30.9] weeks; 264 [59%] female; mean birth
weight, 1210 [range,490-2290]g).Among them,230wereallo-
catedtoreceiverhEPOand220toreceiveplacebo.Afterdischarge
fromtheneonatal intensivecareunit,2 randomizedinfantswho
hadbeenallocatedtotherhEPOgroupwerediagnosedwithasyn-
dromepotentiallyaffectingneurodevelopment.For this reason,
theywere retrospectivelyexcluded fromtheoutcomeanalysis.
The number of randomized infants in 2 previous reports14,15
slightlydiffers fromthat in thepresent reportbecause12 infants
initially includedwere later foundnot tomeet inclusioncriteria.
Baseline characteristics were similar,12 except for a higher
5-minuteApgarscore intherhEPOvsplacebogroup(P = .02),as
wereneonatalmorbidities (Table 1).Theproportionofdropouts
and infants assessed with developmental tests other than the
BSID-IIwerealsosimilarinbothgroups(Figure).Primaryoutcome
datawere collected at age 2 years from 191 infants in the rhEPO
group(83%)and174intheplacebogroup(79%).Meanageatout-
comeassessmentwas23.6monthsandsimilarbetweengroups.
Of450randomized infants,7 (1.5%)receiveda lowerdoseof
rhEPOorplacebothanallocatedand50(11%)receivedsupplemen-
tal rhEPO to treat anemia of prematurity during the neonatal
course. The distributions of these infantswith lower dose (4 in
therhEPOgroupand3intheplacebogroup)andwithsupplemen-
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talrhEPO(27intherhEPOgroupand23intheplacebogroup)were
similar between groups.
Outcome Assessment
Primary Outcome
In the ITTanalysis,MDIwas93.5 (SD, 16.0) in the rhEPOgroup
and94.5 (SD, 17.8) in theplacebogroup. Thedifferenceof −1.0
(95% CI, −4.5 to 2.5; P = .56) was not statistically significant
(Table 2). The sensitivity analysis including infants who died
confirmed this result (eTable 1 in Supplement 2).
In the per-protocol analysis, the mean difference in MDI
was also not significant, ie, −0.7 (95% CI, −3.0 to 4.4; P = .70)
(eTable 2 in Supplement 2).
Secondary Outcomes
A secondary outcome, PDI, was 89.5 (SD, 16.1) in the rhEPO
groupand92.1 (SD, 17.7) in theplacebogroup; thedifferenceof
−2.6 (99% CI, −7.7 to 1.7; P = .15) was not statistically signifi-
cant.Furthersecondaryoutcomes,whichwereuncommon,are
listed in Table 2 and were not statistically significantly differ-
ent between groups. Mean body weight, length, and head cir-
cumference at 2 years were similar between groups (Table 2).
Exploratory Analyses
Survival without severe neurodevelopmental impairment oc-
curredin164infants intherhEPOgroup(84%)and148inthepla-
cebo group (87%) (odds ratio, 0.9 [99% CI, 0.4 to 1.9]; P = .76)
(Table 2). Post hoc subgroup ITT analyses of the comparison of
the primary outcome in infants less than 28 gestationalweeks,
with intraventricularhemorrhagegrade2orgreater, andwhose
cerebralMRIinvestigationhasbeenpreviouslyanalyzed,14,15also
didnotshowstatisticallysignificantdifferencesbetweeninfants
treatedwith rhEPO andplacebo (eTable 3 in Supplement 2).
Discussion
In this randomized, double-blind, placebo-controlled, multi-
center trial enrolling very preterm infants treated with either
earlyhigh-dose rhEPOor salineplaceboafter birth,noeffect of
rhEPOonneurodevelopmental outcomes at 2 years’ corrected
age could be demonstrated. To the best of our knowledge, this
study evaluated the largest population to date of very preterm
infants treatedwithhigh-doserhEPOduringthefirstdaysof life.
It is possible that rhEPO does not have a neuroprotective role.
However, differenceswith previous studies suggest the re-
sults of this studymay be related to the timing and duration of
rhEPOadministration.Twoprevious smaller randomizedclini-
cal trials11,30and2retrospectivestudies10,31demonstratedaben-
eficialeffectofEPO.Incontrast,anotherrandomizedclinical trial
foundnoeffect fromrepeatedadministrationof low-doserhEPO
together with iron supplementation over 6weeks on neurode-
Figure. Participant Flow in the Clinical Trial of Erythropoietin in Preterm Infants
1359 Infants born >26 wk to <32 wk
gestation in 2005-2012
909 Excluded
621 Parents not approached (a priori
palliative care includeda)
26 Participation in another trial
176 Parental refusal
86 Severe congenital malformation
2 Excluded (met exclusion criteria d)
450 Randomized
230 Randomized to receive rhEPO
199 Received rhEPO as randomized
31 Did not receive rhEPO as randomized
4 Received lower dose b
27 Received supplemental
rhEPO c
220 Randomized to receive placebo
194 Received placebo as randomized
26 Did not receive placebo as randomized
3 Received lower dose b
23 Received supplemental
rhEPO c
191 Included in primary analysis (underwent
Bayley Scales of Infant Development II)
39 Excluded
31 Did not undergo follow-up assessment
8 Underwent other developmental test
4 Griffith Mental Development Scales
4 Bayley Scales of Infant and Toddler
Development
174 Included in primary analysis (underwent
Bayley Scales of Infant Development II)
46 Excluded
34 Did not undergo follow-up assessment
12 Underwent other developmental test
8 Griffith Mental Development Scales
4 Bayley Scales of Infant and Toddler
Development
199 Underwent follow-up assessment
29 Did not undergo follow-up assessment
16 Dropped out
13 Died
186 Underwent follow-up assessment
34 Did not undergo follow-up assessment
22 Dropped out
12 Died
rhEPO indicates recombinant human
erythropoietin.
a Decision to provide primary
nonintervention and palliative care
after delivery was made antenatally
with the agreement of the parents if
several known prognostic factors
were so unfavorable that the
initiation of intensive care measures
appeared to be inappropriate.
b Infants received lower than
allocated dose because after
randomization, which occurred
before 3 hours of life, exclusion
criteria (n = 5) or nonadherence to
inclusion criteria (attributable to
errors in reporting of gestational
age, n = 2) were discovered for
some infants; thus, they were
excluded after randomization.
c Infants received supplemental
rhEPO later to treat anemia of
prematurity during the neonatal
course.
d Excluded after administration of the
allocated treatment because of a
uniparental disomy 16 and a
dysmorphic syndrome that became
evident after the third day of life
(genetic investigations were still
ongoing at the time of manuscript
submission).
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velopmental outcome measurements in extremely low birth
weightinfantsat18to22months’correctedage.32Thefundamen-
taldifferencesbetweenthesestudiesandthepresentonearethe
samplesizesandthe rhEPOtreatment regimen. In the2smaller
randomized trials, rhEPOwas started later (between day 2 and
4of life), given in lower doses (400 IU/kg),more often (3×/wk),
andoveralongerperiod(upto35weeks’postmenstrualage)than
inthepresentstudy.Therefore,oneof thereasons for the lackof
improvedoutcomewithrhEPOinthis studycouldbethe timing
of the first dose and shorter duration of rhEPO treatment.
In extremely low birth weight infants, high-dose rhEPO
(2500 IU/kg) achieves neuroprotective plasma concentrations
over 12 hours after injection, and in case of repeated adminis-
trations, steady-state conditions are achieved within 24 to 48
hours.33Wedecided on a high-dose regimen over a short dura-
tion immediately after birth to rapidly saturate erythropoietin
receptorswhilereducinganyadverseeffectsofhigh-doserhEPO
treatment.However, inaretrospectiveanalysis,Brownetal31 re-
portedanassociationbetweengreater6-weekcumulativedoses
of rhEPOandhigher cognitive scores assessed by theBSID-II in
very preterm infants at amedian age of 26months, suggesting
a possible dose-response relationship between rhEPO and the
outcomemeasure. The regimenused in this studymight be in-
sufficient inachievingneuroprotectionduring thepostnatalpe-
riod, and the standard application of rhEPO for neuroprotec-
tion in very preterm infants still needs to be clarified.
To date, 2 other large trials have been designed to analyze
theneuroprotective role of rhEPO in very preterm infants: one
is completed (NCT02036073), and the other is still ongoing
(NCT01378273).According to their protocols, rhEPO is given in
lowerdose andmoreoften (ie, 500 IU/kgeveryday for 14days,
beginning at <24 hours of age; and 1000 IU/kg intravenously
every 48 hours for 6 doses, then 400 IU/kg subcutaneously 3
times perweek until 32weeks 6 days postmenstrual age) than
in the present study. The results of these studies should help
in assessment of the different rhEPO strategies.
Inaretrospectivecohortstudyofextremelypreterminfants,
Neubauer et al10 reported improvement in neurodevelopmen-
tal outcome in infantswhowere exposed to EPO and had neo-
natalbrain lesions.Thiswasnotobserved in this trial.However,
lowergestational agegroups, ie, less than26weeks, and infants
withseveremorbidities,suchasmajorbrainlesionsthatcanaffect
neurodevelopment,wereunderrepresentedinthisstudysample,
whichmighthaveprevented identificationofaneuroprotective
roleof rhEPO inhigh-riskpretermsubpopulations. It is surpris-
ing thatwe foundno treatment effect of rhEPOon the primary
outcome,MDI, in the subgroupof study infants inwhichanas-
sociation between rhEPO and reduced incidence of white and
graymatter injuriesattermequivalentwaspreviouslyshown.14,15
However, correlationbetweenquantitativemeasuresusingce-
rebralMRI at term-equivalent age and qualitativemeasures of
cognitiveoutcomeat2years inpreterminfantshasnotbeenes-
tablished,andthesearchfor imagingbiomarkerscontinues.The
neurodevelopmental outcome at age 5 years in this cohortwill
be important. An ongoing trial (NCT02076373) is examining
whether a selected group of very preterm infants with
intraventricularhemorrhagegrade2ormorecouldbenefit from
high-dose rhEPO administered as a rescue therapy.29
Thenegative results of the trial also raise a question about
the timing of measurement of the primary outcome. As re-
cently pointed out by Marlow, assessment of outcomes at 2
years may not be the most appropriate point to assess the ef-
ficacy of an intervention, and the time point may rather re-
flectproofof safety.34Thepredictivevalidityof long-termneu-
rodevelopmental outcome for individuals assessed at 2 years
is relatively poor if infants with major disabilities are
excluded.35-37 Thus, the present study assessing outcomes at
2 years’ corrected age may primarily confirm the previously
reportedsafetyofhigh-dose rhEPOadministration toverypre-
term infants bornbetween26and32weeks’ gestational age.12
Assessment at school agemaybe a bettermeasure of efficacy,
when children’s cognitive performance becomesmore differ-
entiated than at 2 years, and reevaluation of the cohort at this
age is planned. To date there is not enough evidence to sup-
port the administration of rhEPO for neuroprotection in very
preterm infants.
Table 1. ComparisonofBaselineCharacteristicsBetween theStudyGroups
Characteristic
rhEPO
(n = 191)
Placebo
(n = 174)
Gestational age, mean (SD), wk 29.2 (1.6) 29.3 (1.6)
Girls, No. (%) 71 (37) 76 (44)
Singletons, No. (%) 120 (63) 114 (65)
Birth weight, mean (SD), g 1220 (327) 1213 (357)
z score, mean (SD) −0.08 (0.76) −0.13 (0.88)
Birth head circumference,
mean (SD), cm
27.0 (2.0) 26.9 (2.3)
z score, mean (SD) −0.10 (0.65) −0.19 (0.75)
Antenatal steroids
(complete course), No. (%)a
186 (97) 158 (91)
Chorioamnionitis
(placental histology), No. (%)
57 (30) 44 (25)
Umbilical artery pH, mean (SD) 7.32 (0.07) 7.32 (0.08)
Apgar score at 5 min, mean (SD) 7.8 (1.6) 7.3 (2.0)
Mechanical ventilation,
median (IQR), d
0.0 (0.0 to 4.0) 0.0 (0.0 to 3.0)
Bronchopulmonary dysplasia,
No. (%)
66 (34) 64 (37)
IVH grade ≥2, No. (%) 10 (5) 10 (6)
Cystic periventricular leukomalacia,
No. (%)
1 (0.5) 2 (1)
Sepsis, No. (%) 24 (13) 22 (13)
Necrotizing enterocolitis, No. (%) 4 (2) 5 (3)
ROP grade ≥3, No. (%) 1 (0.5) 5 (3)
PDA (treatment needed), No. (%) 55 (29) 44 (25)
Socioeconomic status,
median (IQR)b
6.0 (4.0-6.0) 6.0 (4.0-7.0)
Maternal age, median (IQR), y 33.5 (29.0-37.0) 33.0 (29.0-35.0)
Education of the mother,
median (IQR)c
3.0 (1.0-3.0) 3.0 (1.5-3.0)
Abbreviations: IQR, interquartile range; IVH, intraventricular hemorrhage;
PDA, patent ductus arteriosus; rhEPO, recombinant human erythropoietin;
ROP, retinopathy of prematurity.
a Two doses of 12 mg or 4 doses of 6mg of betamethasone administered
intramuscularly 24 hours apart.
b Twelve-point score classified into higher (score 2-5), middle (6-8), and lower
(9-12) class.29
c Six-point score classified into higher (score 1-2), middle (3-4), and lower (5-6)
education.29
Early Prophylactic High-Dose rhEPO for Very Preterm Infants Original Investigation Research
jama.com (Reprinted) JAMA May 17, 2016 Volume 315, Number 19 2083
Downloaded From: http://jama.jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 07/12/2016
Copyright 2016 American Medical Association. All rights reserved.
Thestrengthsof this study include its randomized,double-
blind, placebo-controlled design and the large sample size.
However, some limitations also need to bementioned. A first
weakness is theadministrationof supplemental rhEPOto treat
anemia in about one-tenth of the whole cohort, and the ad-
ministration of a lower dose of rhEPO or placebo than allo-
cated in 7 infants. Notwithstanding this protocol violation,
similar results were observed in both the ITT and the per-
protocol analyses, making the possibility of bias less rel-
evant.A second limitation is the relatively longdurationof en-
rollment, mainly caused by an 11-month enrollment stop by
the Swissmedic and the ethics committees because of con-
cernabout thedeathofan infantallocatedtotherhEPOgroup.17
A third limitation is that 5 follow-up centerswere involved
in outcomedata collection, potentially increasing variability in
thequantificationofneurodevelopment. To reduce this poten-
tial source of bias, the follow-upexaminationswereperformed
byexperiencedinvestigators,videotaped,anddiscussedatregu-
larmeetings. Fourth, the 19% rate of loss to follow-up is of con-
cern, although6%representeddeceased infants. Fifth, thepla-
cebogrouphadaconsiderablyhigherMDI thanhypothesized in
the planning phase of the study, which may have reduced the
powerofthestudy.Thismighthaveoccurredbecausenopreterm
infants at very high risk for neurodevelopmental problems, ie,
withgestationalage less than26weeksoraffectedbyhigh-grade
intracerebralbleeding,wereenrolled. Inaddition, improvement
inneurodevelopmentaloutcomesofextremelypreterminfants
has been observed in Switzerland over the last decade.38
Conclusions
Among very preterm infants who received prophylactic early
high-dose rhEPO for neuroprotection, compared with in-
fantswho receivedplacebo, therewereno statistically signifi-
cant differences in neurodevelopmental outcomes at 2 years.
Follow-up for cognitive and physical problems that may not
become evident until later in life is required.
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Development Index; rhEPO, recombinant human erythropoietin.
a For primary outcome, 95% CI is reported.
bReported as proportions of 1.
c For rhEPO group, n = 187.
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of children to function andmove around; indicates their need for assistance
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e AnMDI or PDI less than 70 indicates a score below −2 SDs from the norm.
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